Analysts are intrested in these 5 stocks: ( (CHRD) ), ( (INMD) ), ( (UPST) ), ( (BBIO) ) and ( (ATXS) ). Here is a breakdown of their recent ratings and the rationale behind them.
Chord Energy is making waves in the energy sector with its recent operational successes. Analyst Noah Hungness has upgraded the stock to a ‘Buy’ with a price objective of $114, citing improved capital efficiency and a peer-leading balance sheet. The company has successfully drilled its first 4-mile lateral well, coming in under budget and ahead of schedule, which has significantly lowered maintenance capital expenditure estimates. With a strong balance sheet and a catalyst-rich path forward, Chord Energy is poised to navigate the volatile oil market effectively.
InMode, on the other hand, is facing challenges in the medical aesthetics market. Analyst Sam Eiber has downgraded the stock to ‘Hold’ due to persistent macroeconomic challenges and a lack of offsets. Despite the company’s strong balance sheet and premium product offerings, the market environment remains tough, with revenue guidance likely to be revised downward if conditions don’t improve. However, InMode’s long-term prospects remain positive once market conditions stabilize.
Upstart Holdings is seeing a shift in its fortunes as analyst Mihir Bhatia upgrades the stock to ‘Hold’. The company’s diverse loan product offerings and improved funding sources have balanced the risk-reward at current levels. With upcoming catalysts like the AI Investor Day and stable loan volumes, Upstart is well-positioned to capitalize on its growth prospects. The stock’s valuation is now more in line with its growth potential, making it an attractive option for investors.
BridgeBio Pharma is off to a strong start with its new product, Attruby, exceeding sales expectations. Analyst Tyler Van Buren has initiated coverage with a ‘Buy’ rating and a $60 price target. The company’s Q1 sales of Attruby significantly surpassed expectations, driven by high demand and improved conversion rates. With a growing number of prescriptions and a promising revenue outlook, BridgeBio is set to achieve substantial growth in the coming years.
Astria Therapeutics is gaining attention with its innovative approach to treating hereditary angioedema. Analyst Steven Seedhouse has initiated coverage with a ‘Buy’ rating and a $47 price target. The company’s lead product, navenibart, is expected to outperform existing therapies due to its superior efficacy and convenience. With ongoing Phase 3 trials and a promising pipeline, Astria is well-positioned to capture a significant share of the market.